299 related articles for article (PubMed ID: 33738175)
21. Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases.
Aapro M; Saad F; Costa L
Oncologist; 2010; 15(11):1147-58. PubMed ID: 21051658
[TBL] [Abstract][Full Text] [Related]
22. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
23. Use of bone-modifying agents among breast cancer patients with bone metastasis: evidence from oncology practices in the US.
McGrath LJ; Overman RA; Reams D; Cetin K; Liede A; Narod SA; Brookhart MA; Hernandez RK
Clin Epidemiol; 2018; 10():1349-1358. PubMed ID: 30288124
[TBL] [Abstract][Full Text] [Related]
24. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
Stopeck AT; Lipton A; Body JJ; Steger GG; Tonkin K; de Boer RH; Lichinitser M; Fujiwara Y; Yardley DA; Viniegra M; Fan M; Jiang Q; Dansey R; Jun S; Braun A
J Clin Oncol; 2010 Dec; 28(35):5132-9. PubMed ID: 21060033
[TBL] [Abstract][Full Text] [Related]
25. Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline.
Dhesy-Thind S; Fletcher GG; Blanchette PS; Clemons MJ; Dillmon MS; Frank ES; Gandhi S; Gupta R; Mates M; Moy B; Vandenberg T; Van Poznak CH
J Clin Oncol; 2017 Jun; 35(18):2062-2081. PubMed ID: 28618241
[TBL] [Abstract][Full Text] [Related]
26. Clinical value of serum bone resorption markers for predicting clinical outcomes after use of bone modifying agents in metastatic bone tumors: A prospective cohort study.
Urakawa H; Ando Y; Hase T; Kikumori T; Arai E; Maeda O; Mitsuma A; Sugishita M; Shimokata T; Ikuta K; Ishiguro N; Nishida Y
Int J Cancer; 2020 Jun; 146(12):3504-3515. PubMed ID: 31846063
[TBL] [Abstract][Full Text] [Related]
27. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel.
Hillner BE; Ingle JN; Berenson JR; Janjan NA; Albain KS; Lipton A; Yee G; Biermann JS; Chlebowski RT; Pfister DG
J Clin Oncol; 2000 Mar; 18(6):1378-91. PubMed ID: 10715310
[TBL] [Abstract][Full Text] [Related]
28. Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors.
Brown-Glaberman U; Stopeck AT
Biologics; 2012; 6():89-99. PubMed ID: 22532777
[TBL] [Abstract][Full Text] [Related]
29. MRONJ in breast cancer patients under bone modifying agents for cancer treatment-induced bone loss (CTIBL): a multi-hospital-based case series.
Mauceri R; Coppini M; Attanasio M; Bedogni A; Bettini G; Fusco V; Giudice A; Graziani F; Marcianò A; Nisi M; Isola G; Leonardi RM; Oteri G; Toro C; Campisi G
BMC Oral Health; 2023 Feb; 23(1):71. PubMed ID: 36739399
[TBL] [Abstract][Full Text] [Related]
30. Uptake of bone-modifying agents in patients with HER2+ metastatic breast cancer with bone metastases - prospective data from a multi-site Australian registry.
Wong V; de Boer R; Dunn C; Anton A; Malik L; Greenberg S; Yeo B; Nott L; Collins IM; Torres J; Barnett F; Nottage M; Gibbs P; Lok SW
Intern Med J; 2022 Oct; 52(10):1707-1716. PubMed ID: 34002929
[TBL] [Abstract][Full Text] [Related]
31. Risk Factors for Development of Hypocalcemia in Patients With Cancer Treated With Bone-Modifying Agents.
White PS; Dennis M; Jones EA; Weinberg JM; Sarosiek S
J Natl Compr Canc Netw; 2020 Apr; 18(4):420-427. PubMed ID: 32259788
[TBL] [Abstract][Full Text] [Related]
32. [Inhibition of RANK ligand to treat bone metastases].
Body JJ
Bull Cancer; 2013 Nov; 100(11):1207-13. PubMed ID: 24158618
[TBL] [Abstract][Full Text] [Related]
33. Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval.
Cadieux B; Coleman R; Jafarinasabian P; Lipton A; Orlowski RZ; Saad F; Scagliotti GV; Shimizu K; Stopeck A
J Bone Oncol; 2022 Apr; 33():100416. PubMed ID: 35242510
[TBL] [Abstract][Full Text] [Related]
34. A Retrospective Analysis of Denosumab for the Treatment of Bone Metastases in Chinese Patients With Breast Cancer.
Li W; Wu X; Yu H; Zhu Z; Li W; Huang X
Clin Med Insights Oncol; 2023; 17():11795549231182266. PubMed ID: 37448470
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of bone-modifying agents among multiple myeloma patients: A retrospective cohort study.
Billias C; Langer M; Ursu S; Schorr R
J Oncol Pharm Pract; 2022 Apr; 28(3):523-529. PubMed ID: 33593137
[TBL] [Abstract][Full Text] [Related]
36. Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis.
Wang Z; Qiao D; Lu Y; Curtis D; Wen X; Yao Y; Zhao H
Oncologist; 2015 Apr; 20(4):440-9. PubMed ID: 25732263
[TBL] [Abstract][Full Text] [Related]
37. Denosumab versus pamidronate in the treatment of osteolytic bone metastases secondary to breast cancer: a multi-institutional analysis.
Bradley M; Nichols M; Miles B
Proc (Bayl Univ Med Cent); 2024; 37(1):26-29. PubMed ID: 38174029
[TBL] [Abstract][Full Text] [Related]
38. Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers.
Alzahrani M; Stober C; Liu M; Awan A; Ng TL; Pond G; Alshamsan B; Vandermeer L; Clemons M
Support Care Cancer; 2022 May; 30(5):3977-3984. PubMed ID: 35059864
[TBL] [Abstract][Full Text] [Related]
39. Development of a Practice Standard for Monitoring Adult Patients Receiving Bone-Modifying Agents at a Community Cancer Center.
Nguyen A; Kalis JA; Sutz TR; Jeffers KD
J Adv Pract Oncol; 2018; 9(6):601-607. PubMed ID: 31186982
[TBL] [Abstract][Full Text] [Related]
40. Risk factors for skeletal-related events in patients with bone metastasis from breast cancer undergoing treatment with zoledronate.
Miyashita H; Cruz C; Malamud S
Breast Cancer Res Treat; 2020 Jul; 182(2):381-388. PubMed ID: 32474744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]